Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
19 Julho 2023 - 5:01PM
Kala Pharmaceuticals, Inc. (Nasdaq:KALA), today announced that the
Company granted non-statutory stock options to a new employee as an
inducement award outside the Company’s Amended and Restated 2017
Equity Incentive Plan in accordance with Nasdaq Listing Rule
5635(c)(4).
The Company granted stock options to purchase up to an aggregate
of 450 shares of its common stock to one new employee. The stock
options were granted on July 14, 2023. The grant was approved by
the Compensation Committee and made as a material inducement to
such employee entering into employment with Kala Pharmaceuticals in
accordance with Nasdaq Listing Rule 5635(c)(4). The option award
has an exercise price of $14.43 per share, the closing price of
Kala Pharmaceuticals’ common stock on July 14, 2023. The options
have a ten-year term and vest over four years, with 25% of the
original number of shares vesting on the first anniversary of the
employee’s new hire date and the remainder vesting in equal monthly
installments over the following three years. Vesting of the options
is subject to the employee’s continued service with Kala
Pharmaceuticals through the applicable vesting dates.
About Kala Pharmaceuticals,
Inc.Kala is a clinical-stage biopharmaceutical company
dedicated to the research, development and commercialization of
innovative therapies for rare and severe diseases of the eye.
Kala’s biologics-based investigational therapies utilize Kala’s
proprietary mesenchymal stem cell secretome (MSC-S) platform.
Kala’s lead product candidate, KPI-012, is a human MSC-S, which
contains numerous human-derived biofactors, such as growth factors,
protease inhibitors, matrix proteins and neurotrophic factors that
can potentially correct the impaired corneal healing that is an
underlying etiology of multiple severe ocular diseases. KPI-012 is
currently in clinical development for the treatment of persistent
corneal epithelial defect (PCED), a rare disease of impaired
corneal healing, for which it has received Orphan Drug and Fast
Track designations from the U.S. Food and Drug Administration. Kala
is also targeting the potential development of KPI-012 for the
treatment of Limbal Stem Cell Deficiency and other rare corneal
diseases that threaten vision and has initiated preclinical studies
to evaluate the potential utility of its MSC-S platform for retinal
degenerative diseases, such as Retinitis Pigmentosa and Stargardt
Disease. For more information on Kala, please visit
www.kalarx.com.
Investor Contacts: Hannah
Deresiewiczhannah.deresiewicz@sternir.com 212-362-1200
KALA BIO (NASDAQ:KALA)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
KALA BIO (NASDAQ:KALA)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024